The estimated Net Worth of Craig Fraser is at least $1.24 Milion dollars as of 27 September 2023. Mr. Fraser owns over 2,500 units of Windtree Therapeutics stock worth over $176,525 and over the last 6 years he sold WINT stock worth over $0. In addition, he makes $1,063,640 as President, Chief Executive Officer a Director at Windtree Therapeutics.
Craig has made over 27 trades of the Windtree Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of WINT stock worth $2,550 on 27 September 2023.
The largest trade he's ever made was buying 7,000 units of Windtree Therapeutics stock on 29 June 2022 worth over $2,940. On average, Craig trades about 1,427 units every 40 days since 2019. As of 27 September 2023 he still owns at least 57,877 units of Windtree Therapeutics stock.
You can see the complete history of Mr. Fraser stock trades at the bottom of the page.
Craig E. Fraser serves as President, Chief Executive Officer, Director of the Company. He brings over 29 years of experience as a leader in product development, fundraising, business development and commercial operations in building biopharmaceutical and device businesses for startups as well as larger companies. Prior to joining us, Mr. Fraser held executive positions at several biopharmaceutical companies, including Novelion as Chief Operating Officer and President from 2014 to 2015 and, prior to that, positions of increasing responsibility; as Vice President of Global Disease Areas at Pfizer from 2009 to 2011 and Vice President and Global Business Manager at Wyeth Pharmaceuticals from 2007 to 2009. Previously, Mr. Fraser served as Vice President, Sales & Marketing and Commercial Operations and as Vice President, Global Strategic Marketing at Johnson & Johnson; and as Gastroenterology Franchise Lead, National Sales Director - Immunology and Acute Cardiovasculars, and Marketing Director - Cardiovasculars and Diagnostics at Centocor and various sales and sales management positions prior to marketing roles. Mr. Fraser is a veteran of both the U.S. Marine Corps and the U.S. Army. Mr. Fraser does not serve on any other public company boards. Mr. Fraser received his B.S. degree in Public Administration from Slippery Rock University of Pennsylvania.
As the President, Chief Executive Officer a Director of Windtree Therapeutics, the total compensation of Craig Fraser at Windtree Therapeutics is $1,063,640. There are no executives at Windtree Therapeutics getting paid more.
Craig Fraser is 55, he's been the President, Chief Executive Officer a Director of Windtree Therapeutics since 2016. There are 12 older and 3 younger executives at Windtree Therapeutics. The oldest executive at Windtree Therapeutics, Inc. is Mary Templeton, 73, who is the Senior Vice President, General Counsel and Corporate Secretary.
Craig's mailing address filed with the SEC is 2600 KELLY ROAD, SUITE 100, WARRINGTON, PA, 18976.
Over the last 6 years, insiders at Windtree Therapeutics have traded over $1,982,541 worth of Windtree Therapeutics stock and bought 6,849,036 units worth $20,224,921 . The most active insiders traders include James Huang, Pharmaceutical Holdings Ltd... a Ii Investments Ltd Lph. On average, Windtree Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $425,323. The most recent stock trade was executed by Craig Fraser on 27 September 2023, trading 2,500 units of WINT stock currently worth $2,550.
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Windtree Therapeutics executives and other stock owners filed with the SEC include: